{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gan L"],"funding":["Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd","NCI NIH HHS","Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd."],"pagination":["2597648"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12777750"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["47(1)"],"pubmed_abstract":["Recombinant human erythropoietin (rhEPO) fused with human immunoglobulin G (IgG) Fc fragment (rhEPO-Fc) is a novel erythropoiesis-stimulating agent designed to extend plasma half-life and enhance biological activity. However, data on the efficacy and safety of rhEPO-Fc in hemodialysis patients with chronic kidney disease (CKD)-related anemia remain limited. This phase 3 trial enrolled patients from 45 Chinese hospitals. Participants were randomized (2:1) to receive either rhEPO-Fc or rhEPO (Chinese hamster ovary cell-derived) for 28 weeks. The rhEPO-Fc responders were eligible for a 24-week extension period. The primary endpoint was the least square mean (LSM) change in hemoglobin (Hb) levels from baseline between weeks 21 and 28. Among 356 rhEPO-Fc and 178 rhEPO recipients, patients recei"],"journal":["Renal failure"],"pubmed_title":["Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study."],"pmcid":["PMC12777750"],"funding_grant_id":["N02 PC025001"],"pubmed_authors":["Wang B","Wen R","Wan X","Zuo L","Wang J","Xiong X","Zhang P","Wu H","Shi Y","Wang P","Ou J","Chen W","Shen Y","Wang Y","Zhang A","Xu K","Yao J","Chen Q","Yang L","Feng X","Xu Q","Li R","Yang A","Xu H","Yang C","Xu J","Li X","Li Y","Gao X","Xiong F","Yi X","Cao N","Long G","Jiang H","Liu P","Qin Y","Zheng H","Jiang X","Yu W","Yu Y","Chang W","Zhang W","Gan L","Peng Q","Liu B","Liu C","Shi J","Zhu Q","Peng J"],"additional_accession":[]},"is_claimable":false,"name":"Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study.","description":"Recombinant human erythropoietin (rhEPO) fused with human immunoglobulin G (IgG) Fc fragment (rhEPO-Fc) is a novel erythropoiesis-stimulating agent designed to extend plasma half-life and enhance biological activity. However, data on the efficacy and safety of rhEPO-Fc in hemodialysis patients with chronic kidney disease (CKD)-related anemia remain limited. This phase 3 trial enrolled patients from 45 Chinese hospitals. Participants were randomized (2:1) to receive either rhEPO-Fc or rhEPO (Chinese hamster ovary cell-derived) for 28 weeks. The rhEPO-Fc responders were eligible for a 24-week extension period. The primary endpoint was the least square mean (LSM) change in hemoglobin (Hb) levels from baseline between weeks 21 and 28. Among 356 rhEPO-Fc and 178 rhEPO recipients, patients recei","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T13:12:35.327Z","creation":"2026-05-30T03:11:43.91Z"},"accession":"S-EPMC12777750","cross_references":{"pubmed":["41481110"],"doi":["10.1080/0886022X.2025.2597648"]}}